Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)-Reference-Cited by-同舟云学术

Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)

Published:2020-09-16 Issue:6 Volume:105 Page:675-681
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Nougier Christophe¹^ORCID,Jeanpierre Emmanuelle²^ORCID,Ternisien Catherine³,Proulle Valérie⁴,Hezard Nathalie⁵,Pouplard Claire⁶,Lasne Dominique⁷⁸,

Affiliation:

1. Laboratoire d'hématologie‐hémostase Centre de Biologie et Pathologie EstHospices civils de Lyon Bron France

2. CHU Lille Institut d'Hématologie TransfusionInserm U1011 Lille France

3. Service d'Hématologie Hémostase, Hôtel‐Dieu CHU de Nantes France

4. Service d'Hématologie Biologique CHU BicètreAP‐HPUniversité Paris Sud SaclayINSERM U1176 Le Kremlin‐Bicêtre France

5. Laboratoire d'hématologie Hôpitaux de Marseille Marseille France

6. Service d'Hématologie Hémostase Hôpital TrousseauCHU de ToursEA 7501 Université François Rabelais Tours France

7. Laboratoire d'hématologie générale Hôpital NeckerAP‐HP Paris France

8. Université Paris Sud Paris Saclay Inserm U1176 Le Kremlin‐Bicêtre France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13490

Reference28 articles.

1. Haute Aurorité de Santé[Internet].https://www.has‐sante.fr/portail/jcms/c_2868847/fr/hemlibra‐emicizumab‐hemostatique. Accessed February 06 2019.

2. Haute Autorité de Santé ‐ HEMLIBRA[Internet]. [cited 2020 Apr 1]. Available fromhttps://www.has‐sante.fr/jcms/p_3114482/fr/hemlibra. Accessed April 1 2020.

3. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

4. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

5. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A;Journal of Thrombosis and Haemostasis;2024-07

2. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data;Journal of Thrombosis and Haemostasis;2024-06

3. L’ère des nanocorps et anticorps thérapeutiques en hémostase;Revue Francophone des Laboratoires;2024-03

4. The effects of time and temperature on the in vitro stability of emicizumab in blood samples: Implications for laboratory and clinical practices;Haemophilia;2023-12-25

5. Functional determination of emicizumab in presence of factor VIII activity;Journal of Thrombosis and Haemostasis;2023-12